<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04155424</url>
  </required_header>
  <id_info>
    <org_study_id>ECU-NMO-303</org_study_id>
    <secondary_id>2019-001829-26</secondary_id>
    <nct_id>NCT04155424</nct_id>
  </id_info>
  <brief_title>A Study of the Safety and Activity of Eculizumab in Pediatric Participants With Relapsing Neuromyelitis Optica Spectrum Disorder</brief_title>
  <official_title>A Phase 2/3 Open-Label, Single-Arm Trial to Evaluate the Safety and Activity of Eculizumab in Pediatric Patients With Relapsing Neuromyelitis Optica Spectrum Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alexion Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alexion Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the safety and efficacy of eculizumab in pediatric&#xD;
      participants (aged 2 to &lt; 18 years) with relapsing neuromyelitis optica spectrum disorder&#xD;
      (NMOSD).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 14, 2020</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">November 2021</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline In The Annualized Relapse Rate At 52/53 Weeks</measure>
    <time_frame>Baseline, Week 52/53</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time To First Relapse</measure>
    <time_frame>Baseline up to Week 52/53</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline In Expanded Disability Status Scale (EDSS) Score At 52/53 Weeks In Participants ≥5 Years Of Age</measure>
    <time_frame>Baseline, Week 52/53</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline In The Hauser Ambulatory Index Score At 52/53 Weeks</measure>
    <time_frame>Baseline, Week 52/53</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline In Pediatric Quality Of Life Inventory (PedsQL) At 52/53 Weeks In Participants ≥5 Years Of Age</measure>
    <time_frame>Baseline, Week 52/53</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline In Pediatric Quality Of Life Inventory Parent Proxy (PedsQL Parent Proxy) At 52/53 Weeks In Participants &lt; 5 Years Of Age</measure>
    <time_frame>Baseline, Week 52/53</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline In Visual Acuity As Measured By The Snellen Or LEA Symbols Eye Chart Examination At 52/53 Weeks</measure>
    <time_frame>Baseline, Week 52/53</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline In Confrontational Visual Fields As Measured During Ophthalmologic Examination At 52/53 Weeks</measure>
    <time_frame>Baseline, Week 52/53</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline In Color Vision As Measured During Ophthalmologic Examination At 52/53 Weeks</measure>
    <time_frame>Baseline, Week 52/53</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Eculizumab Concentration Over Time</measure>
    <time_frame>Baseline through Week 52/53</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Free Complement Protein 5 Concentrations Over Time</measure>
    <time_frame>Baseline through Week 52/53</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In Vitro Hemolytic Activity Over Time</measure>
    <time_frame>Baseline through Week 52/53</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Neuromyelitis Optica</condition>
  <condition>Neuromyelitis Optica Spectrum Disorder</condition>
  <arm_group>
    <arm_group_label>Eculizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All participants will receive open-label eculizumab by intravenous infusion during the Primary Treatment Period, starting on Day 1 and for a total of 52/53 weeks. The dosing regimen will be based on the participant's body weight. As body weight changes during the study, the participant's weight cohort and dose may change accordingly.&#xD;
After completing the 52/53-week Primary Treatment Period, participants may continue receiving eculizumab in the Extension Treatment Period for 104 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eculizumab</intervention_name>
    <description>Following a weight-based weekly dose of eculizumab during an induction phase, participants will receive weight-based doses of eculizumab every 2 weeks during the Primary Treatment Period and Extension Treatment Period.</description>
    <arm_group_label>Eculizumab</arm_group_label>
    <other_name>Soliris</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female participants aged 2 years to &lt; 18 years with body weight ≥ 10 kilograms&#xD;
             (kg).&#xD;
&#xD;
          2. Vaccinated against Neisseria meningitidis within 3 years prior to, or at the time of&#xD;
             initiating eculizumab. Participants who initiate study drug treatment less than 2&#xD;
             weeks after receiving a meningococcal vaccine must receive appropriate prophylactic&#xD;
             antibiotics until 2 weeks after the vaccination.&#xD;
&#xD;
          3. Documented vaccination against haemophilus influenzae type b and streptococcus&#xD;
             pneumoniae infections at least 2 weeks prior to dosing as per local and&#xD;
             country-specific immunization guidelines for the appropriate age group.&#xD;
&#xD;
          4. Anti-aquaporin-4 antibody-positive and diagnosis of NMOSD as defined by the 2015&#xD;
             International Panel for Neuromyelitis Optica Diagnosis criteria.&#xD;
&#xD;
          5. Historical Relapse Rate of at least 2 relapses in the last 2 years, and with at least&#xD;
             1 relapse in the year prior to Screening.&#xD;
&#xD;
          6. EDSS score ≤ 7.&#xD;
&#xD;
          7. Participants who enter the study receiving supportive immunosuppressive therapies&#xD;
             (ISTs) for the prevention of relapse, either in combination or monotherapy, must be on&#xD;
             a stable dosing regimen of adequate duration.&#xD;
&#xD;
          8. Female participants of childbearing potential must have a negative pregnancy test&#xD;
             (serum human chorionic gonadotropin) at Screening and follow protocol-specified&#xD;
             contraception guidance for avoiding pregnancy while on treatment and for 5 months&#xD;
             after the last dose of eculizumab.&#xD;
&#xD;
          9. Male participants with a female spouse/partner of childbearing potential or a pregnant&#xD;
             or breastfeeding spouse or partner must agree to use double barrier contraception&#xD;
             (male condom plus appropriate barrier method for the female partner) while on&#xD;
             treatment and for at least 5 months after the last dose of eculizumab.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Parent or legal guardian is an Alexion employee.&#xD;
&#xD;
          2. Pregnant, breastfeeding, or intending to conceive during the course of the study.&#xD;
&#xD;
          3. Participants known to be human immunodeficiency virus positive or with congenital&#xD;
             immunodeficiency.&#xD;
&#xD;
          4. Unresolved meningococcal or other serious infection.&#xD;
&#xD;
          5. Any unresolved acute or chronic systemic bacterial or other infection that is&#xD;
             clinically significant in the opinion of the Investigator and has not been treated&#xD;
             with appropriate antibiotics.&#xD;
&#xD;
          6. Use of rituximab or other biologicals such as tocilizumab within 6 months prior to&#xD;
             Screening.&#xD;
&#xD;
          7. Use of mitoxantrone within 3 months prior to Screening.&#xD;
&#xD;
          8. Use of intravenous immunoglobulin or plasma exchange within 3 weeks prior to&#xD;
             Screening.&#xD;
&#xD;
          9. Use of immunomodulatory therapies for multiple sclerosis within 3 months prior to&#xD;
             Screening.&#xD;
&#xD;
         10. Has previously received treatment with eculizumab or other complement inhibitors.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Alexion Pharmaceuticals, Inc.</last_name>
    <phone>855-752-2356</phone>
    <email>clinicaltrials@alexion.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of California San Francisco (UCSF)</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94158</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Georgetown University</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20057</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Children's Healthcare of Atlanta</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30329</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Meridian Clinical Research</name>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <zip>20854</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of North Carolina School of Medicine at Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27517</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Stollery Childrens Hospital</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2B7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Hospital for Sick Children SickKids</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G1X8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Georg-August-Universitaet Goettingen - Universitaetsmedizin Goettingen (UMG) Klinik fuer Kinder- und Jugendmedizin, Abt. Neuropaediatrie</name>
      <address>
        <city>Regensburger Straße</city>
        <state>Goettingen</state>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ospedale Policlinico San Martino</name>
      <address>
        <city>Genoa</city>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Neurological Centre of Latium</name>
      <address>
        <city>Rome</city>
        <zip>00178</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Yokohama City University Medical Center</name>
      <address>
        <city>Yokohama</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Sant Joan de Deu</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen Macarena</name>
      <address>
        <city>Sevilla</city>
        <zip>41009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>November 5, 2019</study_first_submitted>
  <study_first_submitted_qc>November 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 7, 2019</study_first_posted>
  <last_update_submitted>July 13, 2021</last_update_submitted>
  <last_update_submitted_qc>July 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Neuromyelitis Optica</keyword>
  <keyword>Neuromyelitis Optica Spectrum Disorder</keyword>
  <keyword>Devic's Disease</keyword>
  <keyword>Transverse Myelitis</keyword>
  <keyword>Optic Neuritis</keyword>
  <keyword>Relapse</keyword>
  <keyword>Eculizumab</keyword>
  <keyword>Soliris</keyword>
  <keyword>CNS Autoimmune Disorders</keyword>
  <keyword>Demyelinating Disorders</keyword>
  <keyword>NMO</keyword>
  <keyword>NMOSD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuromyelitis Optica</mesh_term>
    <mesh_term>Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eculizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

